X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

MORF

Closed

Morphic Holding Inc

56.99
+0.01 (+0.02%)
Last Update: 16 Aug 2024 16:30:00
Yesterday: 56.985
Day's Range: 56.99 - 56.99
Send
When Written:
 
34.33
Morphic Holding Inc is a biopharmaceutical company that focuses on developing oral integrin therapies for the treatment of autoimmune and inflammatory diseases. The company's lead product candidate, MORF-057, is an oral integrin inhibitor that is being developed for the treatment of inflammatory bowel disease (IBD).

Morphic Holding Inc was founded in 2015 and is headquartered in Waltham, Massachusetts. The company went public in 2018 and is listed on the NASDAQ stock exchange under the ticker symbol MORF.

The company's approach to drug development is based on the concept of integrins, which are proteins that play a key role in cell adhesion and signaling. By targeting specific integrins, Morphic Holding Inc believes it can develop therapies that are more effective and have fewer side effects than current treatments for autoimmune and inflammatory diseases.

Morphic Holding Inc has partnerships with several pharmaceutical companies, including AbbVie, Janssen Biotech, and Schrödinger, to develop integrin-based therapies for a range of diseases. The company's management team includes experienced biotech executives and scientists with expertise in drug discovery and development.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.209
X